#USA #Financial Performance #Denver #DaVita Inc. #Clinical Excellence

DaVita Inc. Q1 2026 Financial Results

On May 5, 2026, DaVita Inc. (NYSE: DVA) announced its financial and operational results for the quarter ended March 31, 2026. The company reiterated its commitment to clinical excellence, emphasizing a foundation built on rigorous operational standards that ensure sustainable results. Javier Rodriguez, the CEO of DaVita, stated, "DaVita's foundation is clinical excellence, driven by operating rigor that produces durable results. We have consistently delivered exceptional clinical outcomes and strong financial performance, and this quarter is no exception."

Financial and Operating Highlights

DaVita's consolidated revenues reached $3.416 billion, with an operating income of $482 million. The diluted earnings per share from continuing operations stood at $2.87, while the operating cash flow amounted to $321 million, leading to a free cash flow of $140 million. Notably, the company repurchased 3.0 million shares of its common stock at an average price of $133.70 per share.

Year-on-Year and Quarter Comparisons

In comparing the performance to previous quarters, the net income attributable to DaVita Inc. came in at $198 million for Q1 2026, a rise from $163 million in Q1 2025. The diluted earnings per share showed a significant increase, enhancing from $2.00 the previous year to $2.87 this quarter.

Key Metrics for Q1 2026

• - Operating Income: $482 million (down from $561 million in Q4 2025)
• - Operating Income Margin: 14.1%
• - Average Treatments Per Day: 91,650 treatments
• - Average Revenue Per Treatment: $417.59
• - Patient Care Cost Per Treatment: $280.11

Dialysis Metrics

In the first quarter, DaVita provided 7,029,525 dialysis treatments, marking an average of 91,650 treatments per day, reflecting a 0.05% increase in daily treatments compared to the previous quarter. The normalized non-acquired treatment growth year-over-year was 0.1%.

Cost Management

The quarterly changes in revenue were primarily influenced by seasonal factors regarding co-insurance and deductibles, as well as fluctuations that were partially offset by increases in average reimbursement rates—including Medicare rate adjustments. Other costs saw increases due to higher compensation and insurance expenses alongside reduced health benefits expenses.

Share Repurchase Program

During the first three months of 2026, DaVita repurchased shares contributing to its commitment to return value to shareholders. Following March 31, an additional 2.0 million shares were repurchased at an average price of $149.81 per share. The ongoing share repurchase program reflects the company’s strategy to enhance shareholder value amid robust financial performance.

Outlook

Looking ahead, DaVita has provided guidance anticipating continued operational growth. The diluted net income from continuing operations per share for the full year is expected to be between $14.10 and $15.20. This range reflects the company’s confidence in achieving consistent financial performance despite external challenges.

Conclusion

DaVita Inc.'s results for the first quarter of 2026 underscore its ability to combine clinical advancements with sound financial strategies. The company's focus on enhancing patient care while achieving fiscal stability positions it favorably amidst a dynamic healthcare marketplace. The outlook remains optimistic as DaVita continues to navigate challenges and leverage opportunities for growth in the dialysis services sector.

• ---

For further details regarding DaVita Inc.'s quarterly results, please refer to their Investor Relations page for the complete financial report and upcoming conference call information.